DOCSLIB.ORG

Structural Determinants of Ligand Binding Selectivity Between the Peroxisome Proliferator- Activated Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structural Determinants of Ligand Binding Selectivity Between the Peroxisome Proliferator- Activated Receptors Structural determinants of ligand binding selectivity between the peroxisome proliferator- activated receptors H. Eric Xu*, Millard H. Lambert†, Valerie G. Montana, Kelli D. Plunket, Linda B. Moore, Jon L. Collins, Jeffery A. Oplinger, Steven A. Kliewer, Robert T. Gampe, Jr., David D. McKee, John T. Moore, and Timothy M. Willson‡ Nuclear Receptor Discovery Research, GlaxoSmithKline, Research Triangle Park, NC 27709 Edited by Michael G. Rosenfeld, University of California at San Diego, La Jolla, CA, and approved September 27, 2001 (received for review August 3, 2001) The peroxisome proliferator-activated receptors (PPARs) are tran- to an even wider range of FAs than either PPAR␥ or PPAR␦ scriptional regulators of glucose, lipid, and cholesterol metabolism. (10). However, no structure of the PPAR␣ LBD has been We report the x-ray crystal structure of the ligand binding domain available to explain these differences in ligand binding proper- of PPAR␣ (NR1C1) as a complex with the agonist ligand GW409544 ties. We now report the structure of the PPAR␣ LBD and the and a coactivator motif from the steroid receptor coactivator 1. identification of key determinants of ligand binding selectivity Through comparison of the crystal structures of the ligand binding between the three PPAR subtypes. domains of the three human PPARs, we have identified molecular determinants of subtype selectivity. A single amino acid, which is Materials and Methods tyrosine in PPAR␣ and histidine in PPAR␥, imparts subtype selec- Reagents and Assays. Rosiglitazone, pioglitazone, and farglitazar tivity for both thiazolidinedione and nonthiazolidinedione ligands. were synthesized as described (11). The synthesis of GW409544 The availability of high-resolution cocrystal structures of the three will be described elsewhere. Expression plasmids for the human PPAR subtypes will aid the design of drugs for the treatments of PPAR-GAL4 chimeras were prepared by inserting amplified metabolic and cardiovascular diseases. cDNAs encoding the LBDs into a modified pSG5 expression vector (Stratagene) containing the GAL4 DNA binding domain eroxisome proliferator-activated receptor (PPAR) ␣ (amino acids 1–147) and the simian virus 40 large T antigen P(NR1C1), PPAR␥ (NR1C3), and PPAR␦ (NR1C2) are nuclear localization signal (APKKKRKVG). For generation of members of the nuclear receptor family of ligand-activated the Y314H PPAR␣ mutant, the Tyr-314 codon (TAT nucleotide transcription factors that bind to fatty acids (FAs) and their sequence) was altered to a His codon (CAT) by Quick-Change metabolites (1). Although the PPARs were originally cloned as Mutagenesis (Stratagene). For generation of the H323Y PPAR␥ orphan receptors, their role in mammalian physiology has been mutant the His-323 codon (CAC) was altered to a Tyr codon uncovered through a process of reverse endocrinology (2) using (TAC). Cell-based reporter assays were performed by transient ␣ transfection in CV-1 cells using (UAS)5-tk-SPAP reporter con- high-affinity synthetic ligands as chemical tools. PPAR is the MEDICAL SCIENCES receptor for the fibrate class of lipid-lowering drugs (3), and structs as described (11). Transfections were performed using PPAR␥ is the receptor for the thiazolidinedione (TZD) class of Lipofectamine (Life Technologies, Grand Island, NY) according antidiabetic drugs (4). Recently, the function of PPAR␦ in the to the manufacturer’s instructions. A ␤-galactosidase expression regulation of reverse cholesterol transport and high-density plasmid was included in each transfection for use as a normal- lipoprotein metabolism was revealed through the use of a potent ization control. PPAR␦ agonist, GW501516 (5). Thus, the PPARs are FA- activated receptors that function as key regulators of glucose, Protein Expression. The human PPAR␣ LBD (amino acids 192– lipid, and cholesterol metabolism. 468 of GenBank No. S74349) tagged with MKKGHHHHHHG The marketed TZDs rosiglitazone and pioglitazone are effec- was expressed from the T7 promoter of plasmid vector pRSETA. tive glucose-lowering drugs that produce modest effects on lipids Bacterial cells (BL21DE3) transformed with this expression in patients with type 2 diabetes (1). Most diabetic patients have vector were grown at 24°C in 2YT broth with 50 mg͞liter Ϸ an abnormal lipid profile, including low levels of high density carbenicillin in shaker flasks to an OD600 of 5.0. Cells were lipoprotein and high levels of triglycerides, which may contribute harvested, resuspended with 20 ml of extract buffer (20 mM to their greatly increased burden of cardiovascular disease. Hepes, pH 7.5͞50 mM imidazole͞250 mM NaCl, and a trace of There is a resurgence of interest in the development of new lysozyme) per liter of cells and sonicated for 20 min on ice. The antidiabetic drugs that combine the insulin-sensitizing effects of lysed cells were centrifuged at 40,000 ϫ g for 40 min, and the PPAR␥ activation with the additional lipid-modifying activity of supernatant was loaded on a 100-ml Ni-agarose column. The the other PPAR subtypes. For example, the L-tyrosine analogue farglitazar (GI262570) has robust effects on glucose, high- density lipoprotein, and triglycerides in diabetic patients (6). The This paper was submitted directly (Track II) to the PNAS office. triglyceride-lowering activity of farglitazar may be a result of its Abbreviations: PPAR, peroxisome proliferator-activated receptor; TZD, thiazolidinedione; activity on PPAR␣. Although farglitazar is 1,000 times less LBD, ligand binding domain; FA, fatty acid; SRC1, steroid receptor coactivator 1. ␣ Data deposition: The atomic coordinates and structure factors have been deposited in the potent on PPAR , its peak plasma levels are above the EC50 for activation of this subtype (1, 6). Additional insight into the Protein Data Bank, www.rcsb.org (PDB ID codes 1K7L and 1K74). molecular determinants of PPAR subtype selectivity may have *To whom correspondence on the structure determination and requests for materials should be addressed. E-mail: [email protected]. important applications in the design of new diabetes drugs. ␥ ␦ †To whom correspondence on molecular modeling should be addresssed. E-mail: X-ray crystal structures of the PPAR and PPAR ligand [email protected]. binding domains (LBDs) revealed that the receptors contain a ‡To whom additional correspondence and reprint requests should be addressed. E-mail: much larger ligand binding pocket than other nuclear receptors [email protected]. (7–10). The size of this pocket may explain the ability of the The publication costs of this article were defrayed in part by page charge payment. This PPARs to bind a variety of naturally occurring and synthetic article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. lipophilic acids. Remarkably, PPAR␣ has been reported to bind §1734 solely to indicate this fact. www.pnas.org͞cgi͞doi͞10.1073͞pnas.241410198 PNAS ͉ November 20, 2001 ͉ vol. 98 ͉ no. 24 ͉ 13919–13924 Downloaded by guest on October 2, 2021 column was washed with 150 ml of buffer A (10% glycerol͞20 Table 1. Statistics of crystallographic data and structures mM Hepes, pH 7.5͞25 mM imidazole), and the protein was ␣͞ ␥͞ ␣͞ ͞ PPAR SRC1 PPAR RXR SRC1 eluted with a 450-ml gradient to buffer B (10% glycerol 20 mM Crystals with GW409544 with GW409544 Hepes, pH 7.5͞500 mM imidazole). The protein, which eluted at 20% buffer B, was diluted with 1 vol of buffer C (20 mM Hepes, Space group P212121 P212121 pH 7.5͞1 mM EDTA) and loaded on a 100-ml S-Sepharose Resolution, Å 20.0–2.5 20.0–2.3 column. The column was washed with a 100-ml buffer C, and the Unique reflections, N 49,991 24,986 PPAR␣ LBD was eluted with a 200-ml gradient to buffer D (20 Completeness, % 99.9 97.3 mM Hepes, pH 7.5͞10 mM DTT͞1 M ammonium acetate). The I͞␴ (last shell) 48.3 (5.7) 28.9 (3.3) PPAR␣ LBD was eluted from the column at 43% buffer D, Rsym*, % 5.4 5.7 which yielded 9 mg of protein per liter of cells, and was Ͼ95% Refinement statistics pure as determined by SDS͞PAGE analysis. The protein was R factor†,% 24.7 23.8 then diluted to 1 mg͞ml with buffer C such that the final buffer R free, % 28.5 27.9 composition was 220 mM ammonium acetate͞20 mM Hepes, pH rmsd‡ bond lengths, Å 0.012 0.011 7.5͞1 mM EDTA͞1 mM DTT. The diluted protein was ali- rmsd bond angles, ° 1.550 1.515 quoted, frozen, and stored at Ϫ80°C. The protein–ligand com- Total nonhydrogen atoms 9312 4408 plexes were prepared by adding 5-fold excess of GW409544 and *Rsym ϭ͚͉Iavg Ϫ Ii͉͚͞Ii. a 2-fold excess of a peptide from the steroid receptor coactivator † Rfactor ϭ͚͉FP Ϫ FPcalc͉͚͞Fp, where Fp and Fpcalc are observed and calculated 1 (SRC1) containing the sequence HSSLTERHKILHR- structure factors, Rfree is calculated from a randomly chosen 10% of reflec- LLQEGSPS (LxxLL motif underlined) and were concentrated to tions excluded from the refinement, and Rfactor is calculated for the remaining 10 mg͞ml. The PPAR␥͞RXR␣ heterodimer complex with 90% of reflections. GW409544 and 9-cis-retinoic acid was prepared as reported (9). ‡rmsd, the rms deviation from ideal geometry. Crystallization and Data Collection. The PPAR␣͞GW409544͞ SRC1 crystals were grown at room temperature in hanging drops lished results). GW409544 contains a vinylogous amide as the containing 1 ␮l of the protein–ligand solution and 1 ␮l of well L-tyrosine N-substituent, which contains three fewer carbon buffer (50 mM bis-Tris-propane, pH 7.5͞4–6% PEG 3350͞150 atoms than the benzophenone found in farglitazar. Aside from mM NaNO ͞16% 2,5-hexanediol͞1–3mMYCl). Before data this difference, the chemical structures of the compounds are 3 3 ␣ ϭ collection, crystals were transiently mixed with the well buffer identical. GW409544 activates PPAR with EC50 2.3 nM and ␥ ϭ ␦ that contained an additional 10% hexanediol and then were PPAR with EC50 0.28 nM, but shows no activation of PPAR ␮ flash-frozen in liquid nitrogen.
Load more

Recommended publications
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • Synthesis of a Coumarin-Based PPAR Fluorescence Probe for Competitive Binding Assay
    International Journal of Molecular Sciences Article Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay Chisato Yoshikawa, Hiroaki Ishida , Nami Ohashi and Toshimasa Itoh * Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan; [email protected] (C.Y.); [email protected] (H.I.); [email protected] (N.O.) * Correspondence: [email protected] Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a molecular target of metabolic syndrome and inflammatory disease. PPARγ is an important nuclear receptor and numerous PPARγ ligands were developed to date; thus, efficient assay methods are important. Here, we investigated the incorporation of 7-diethylamino coumarin into the PPARγ agonist rosiglitazone and used the com- pound in a binding assay for PPARγ. PPARγ-ligand-incorporated 7-methoxycoumarin, 1, showed weak fluorescence intensity in a previous report. We synthesized PPARγ-ligand-incorporating coumarin, 2, in this report, and it enhanced the fluorescence intensity. The PPARγ ligand 2 main- tained the rosiglitazone activity. The obtained partial agonist 6 appeared to act through a novel mechanism. The fluorescence intensity of 2 and 6 increased by binding to the ligand binding domain (LBD) of PPARγ and the affinity of reported PPARγ ligands were evaluated using the probe. Keywords: PPARγ ligand; coumarin; fluorescent ligand; screening; crystal structure Citation: Yoshikawa, C.; Ishida, H.; Ohashi, N.; Itoh, T. Synthesis of a Coumarin-Based PPARγ 1. Introduction Fluorescence Probe for Competitive Binding Assay. Int. J. Mol. Sci. 2021, Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor su- 22, 4034.
    [Show full text]
  • Entropy Drives Selective Fluorine Recognition in the Fluoroacetyl–Coa
    Entropy drives selective fluorine recognition in PNAS PLUS the fluoroacetyl–CoA thioesterase from Streptomyces cattleya Amy M. Weeksa,1,2, Ningkun Wanga,1,3, Jeffrey G. Peltonb, and Michelle C. Y. Changa,c,4 aDepartment of Chemistry, University of California, Berkeley, CA 94720-1460; bQB3 Institute, University of California, Berkeley, CA 94720-1460; and cDepartment of Molecular and Cell Biology, University of California, Berkeley, CA 94720-1460 Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved January 17, 2018 (received for review September 28, 2017) Fluorinated small molecules play an important role in the design of ognition of the fluorine substituent itself, the high polarization of bioactive compounds for a broad range of applications. As such, the C-F bond creates an opportunity for dipolar interactions to there is strong interest in developing a deeper understanding of occur with protein-based functional groups (14, 15), which appears how fluorine affects the interaction of these ligands with their to play a key role in the increased potency of ciprofloxacin (Cipro) targets. Given the small number of fluorinated metabolites iden- compared with analogs lacking the fluorine substituent (16, 17). tified to date, insights into fluorine recognition have been pro- Despite the strong interest in fluorine–protein interactions, vided almost entirely by synthetic systems. The fluoroacetyl–CoA there are few systems in which evolutionarily optimized inter- thioesterase (FlK) from Streptomyces cattleya thus provides a actions between ligand and receptor can be studied given the unique opportunity to study an enzyme–ligand pair that has been limited existence of naturally occurring fluorinated metabolites evolutionarily optimized for a surprisingly high 106 selectivity for a and macromolecules that interact with them.
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • The Selectivity of the Na /K
    RESEARCH ARTICLE The selectivity of the Na+/K+-pump is controlled by binding site protonation and self-correcting occlusion Huan Rui1, Pablo Artigas2, BenoıˆtRoux1* 1Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, United States; 2Department of Cell Physiology and Molecular Biophysics, Texas Tech University Health Sciences Center, Lubbock, United States Abstract The Na+/K+-pump maintains the physiological K+ and Na+ electrochemical gradients across the cell membrane. It operates via an ’alternating-access’ mechanism, making iterative transitions between inward-facing (E1) and outward-facing (E2) conformations. Although the general features of the transport cycle are known, the detailed physicochemical factors governing the binding site selectivity remain mysterious. Free energy molecular dynamics simulations show that the ion binding sites switch their binding specificity in E1 and E2. This is accompanied by small structural arrangements and changes in protonation states of the coordinating residues. Additional computations on structural models of the intermediate states along the conformational transition pathway reveal that the free energy barrier toward the occlusion step is considerably increased when the wrong type of ion is loaded into the binding pocket, prohibiting the pump cycle from proceeding forward. This self-correcting mechanism strengthens the overall transport selectivity and protects the stoichiometry of the pump cycle. DOI: 10.7554/eLife.16616.001 Introduction *For correspondence: roux@ The Na+/K+-pump is a primary active membrane transporter present in nearly all animal cells. It uchicago.edu belongs to the P-type ATPase family, which utilizes the energy released from ATP hydrolysis to Competing interests: The move ions against their concentration gradients across a membrane barrier.
    [Show full text]
  • Regulation of Enac-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors
    Hindawi Publishing Corporation PPAR Research Volume 2010, Article ID 703735, 9 pages doi:10.1155/2010/703735 Review Article Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors Tengis S. Pavlov,1 John D. Imig,2, 3 and Alexander Staruschenko1, 4 1 Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 2 Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 3 Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA 4 Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA Correspondence should be addressed to Alexander Staruschenko, [email protected] Received 6 January 2010; Revised 16 March 2010; Accepted 14 April 2010 Academic Editor: Tianxin Yang Copyright © 2010 Tengis S. Pavlov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peroxisome proliferator-activated receptors (PPARs) are members of a steroid hormone receptor superfamily that responds to changes in lipid and glucose homeostasis. Peroxisomal proliferator-activated receptor subtype γ (PPARγ)hasreceivedmuch attention as the target for antidiabetic drugs, as well as its role in responding to endogenous compounds such as prostaglandin J2. However, thiazolidinediones (TZDs), the synthetic agonists of the PPARγ are tightly associated with fluid retention and edema, as potentially serious side effects. The epithelial sodium channel (ENaC) represents the rate limiting step for sodium absorption in the renal collecting duct. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. The role of PPARγ agonists on ENaC activity remains controversial.
    [Show full text]
  • Directed Evolution of a G Protein-Coupled Receptor for Expression, Stability, and Binding Selectivity
    Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity Casim A. Sarkar*†‡, Igor Dodevski*†, Manca Kenig*§, Stefan Dudli*, Anja Mohr*, Emmanuel Hermans¶, and Andreas Plu¨ckthun*ʈ *Biochemisches Institut, Universita¨t Zu¨ rich, Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland; and ¶Laboratoire de Pharmacologie Expe´rimentale, Universite´catholique de Louvain, Avenue Hippocrate 54.10, B-1200 Bruxelles, Belgium. Edited by William F. DeGrado, University of Pennsylvania, Philadelphia, PA, and approved July 18, 2008 (received for review April 1, 2008) We outline a powerful method for the directed evolution of sequence of a GPCR, keeping all other variables constant, to integral membrane proteins in the inner membrane of Escherichia yield more functionally expressed protein in a convenient het- coli. For a mammalian G protein-coupled receptor, we arrived at a erologous host, Escherichia coli. We used as a model system the sequence with an order-of-magnitude increase in functional ex- rat neurotensin receptor-1 (NTR1), which has been shown to pression that still retains the biochemical properties of wild type. give a detectable yield in E. coli (10, 11) but which still needs to This mutant also shows enhanced heterologous expression in be improved to allow more convenient preparation of milligram eukaryotes (12-fold in Pichia pastoris and 3-fold in HEK293T cells) quantities of receptor. and greater stability when solubilized and purified, indicating that Detailed characterization of the best variant from the selec- the biophysical properties of the protein had been under the tion reported here reveals that it exhibits an order-of-magnitude pressure of selection.
    [Show full text]
  • Bisphenol a Binding Promiscuity
    Research Article Bisphenol A Binding Promiscuity: A Virtual Journey through the Universe of Proteins Elena Lo Piparo1#, Lydia Siragusa2#, Frederic Raymond3, Giovanna Ilaria Passeri2, Gabriele Cruciani4 and Benoît Schilter1 1Food Safety Research, Nestlé Research, Lausanne, Switzerland; 2Molecular Discovery Limited, London, UK; 3Multi-Omics Profiling, Nestlé Research, Lausanne, Switzerland; 4Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy Abstract Significant efforts are currently being made to move toxicity testing from animal experimentation towards human-relevant, mechanism-based approaches. In this context, the identification of the molecular target(s) responsible for mechanisms of action is an essential step. Inspired by the recent concept of polypharmacology (the ability of drugs to interact with mul- tiple targets), we argue that whole proteome virtual screening may become a breakthrough tool in toxicology as it reflects the true complexity of chemical-biological interactions. We investigated the value of performing ligand-protein binding prediction screening across the full proteome to identify new mechanisms of action for food chemicals. We applied the new approach to make a broader comparison between bisphenol A (BPA) (food-packaging chemical) and the endog- enous estrogen 17β-estradiol (EST). Applying a novel, high-throughput ligand-protein binding prediction tool (BioGPS) using the Amazon Web Services (AWS) cloud (to speed-up the calculation), we investigated the value of performing in silico screening across the full proteome (all human and rodent x-ray protein structures available in the Protein Data Bank). The strong correlation between in silico predictions and available in vitro data demonstrated the high predictive power of the method. The most striking result was that BPA was predicted to bind to many more proteins than previously described, most of which also appear to bind EST.
    [Show full text]
  • Human Pharmacology of Positive GABA-A Subtype-Selective Receptor Modulators for the Treatment of Anxiety
    www.nature.com/aps REVIEW ARTICLE Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety Xia Chen1,2,3,4, Joop van Gerven4,5, Adam Cohen4 and Gabriel Jacobs4 Anxiety disorders arise from disruptions among the highly interconnected circuits that normally serve to process the streams of potentially threatening stimuli. The resulting imbalance among these circuits can cause a fundamental misinterpretation of neural sensory information as threatening and can lead to the inappropriate emotional and behavioral responses observed in anxiety disorders. There is considerable preclinical evidence that the GABAergic system, in general, and its α2- and/or α5-subunit- containing GABA(A) receptor subtypes, in particular, are involved in the pathophysiology of anxiety disorders. However, the clinical efficacy of GABA-A α2-selective agonists for the treatment of anxiety disorders has not been unequivocally demonstrated. In this review, we present several human pharmacological studies that have been performed with the aim of identifying the pharmacologically active doses/exposure levels of several GABA-A subtype-selective novel compounds with potential anxiolytic effects. The pharmacological selectivity of novel α2-subtype-selective GABA(A) receptor partial agonists has been demonstrated by their distinct effect profiles on the neurophysiological and neuropsychological measurements that reflect the functions of multiple CNS domains compared with those of benzodiazepines, which are nonselective, full GABA(A) agonists. Normalizing the undesired pharmacodynamic side effects against the desired on-target effects on the saccadic peak velocity is a useful approach for presenting the pharmacological features of GABA(A)-ergic modulators. Moreover, combining the anxiogenic symptom provocation paradigm with validated neurophysiological and neuropsychological biomarkers may provide further construct validity for the clinical effects of novel anxiolytic agents.
    [Show full text]
  • Determination of the in Vivo Selectivity of a New K-Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus Monkey
    Journal of Nuclear Medicine, published on August 5, 2013 as doi:10.2967/jnumed.112.118877 Determination of the In Vivo Selectivity of a New k-Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus Monkey Su Jin Kim1,2, Ming-Qiang Zheng1,2, Nabeel Nabulsi1, David Labaree1, Jim Ropchan1, Soheila Najafzadeh1, Richard E. Carson1–3, Yiyun Huang1,2, and Evan D. Morris1–4 1Yale PET Center, Yale University, New Haven, Connecticut; 2Department of Diagnostic Radiology, Yale University, New Haven, Connecticut; 3Department of Biomedical Engineering, Yale University, New Haven, Connecticut; and 4Department of Psychiatry, Yale University, New Haven, Connecticut results in conditioned place aversion in animals, and dynorphin 11C-LY2795050 is a novel k-selective antagonist PET tracer. The in activation of KOR results in decreased dopamine release in the vitro binding affinities (Ki) of LY2795050 at the k-opioid (KOR) and brain reward circuitry (1,2). The involvement of the KOR in m-opioid (MOR) receptors are 0.72 and 25.8 nM, respectively. Thus, addiction is thought to be through its ability to modulate dopa- the in vitro KOR/MOR binding selectivity is about 36:1. Our goal in mine function. Activation of the KOR by dynorphin or admin- this study was to determine the in vivo selectivity of this new KOR istration of KOR agonists inhibits psychostimulant-induced do- ED antagonist tracer in the monkey. Methods: To estimate the 50 pamine release. Attenuation of dopamine release has been shown value (dose of a compound [or drug] that gives 50% occupancy of to inhibit both the psychomotor effects and the reinforcing be- the target receptor) of LY2795050 at the MOR and KOR sites, 2 series of blocking experiments were performed in 3 rhesus monkeys haviors of psychostimulants.
    [Show full text]
  • Modulation of Cardiometabolic Syndrome Through Peroxisome Proliferator Activator Receptors (Ppars)
    Current Molecular Pharmacology, 2012, 5, 241-247 241 This review is part of a Special Issue on PPAR Ligands and Cardiovascular Disorders: Friend or Foe. This Special Issue carries the following articles: Editorial: PPAR Ligands and Cardiovascular Disorders: Friend or Foe • The involvement of PPARs in the causes, consequences and mechanisms for correction of cardiac lipotoxicity and oxidative stress. • Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activator receptors (PPARs). • Effects of PPARγ agonists against vascular and renal dysfunction. • Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? • Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: A translational medicine perspective. • Peroxisome proliferator-activated receptorγ (PPARγ) agonists on glycemic control, lipid profile and cardiovascular risk. • Effects of PPARγ ligands on vascular tone. • PPARγ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Pitchai Balakumar and Gowraganahalli Jagadeesh Guest Editors Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs) Tom Hsun-Wei Huang* and Basil D. Roufogalis Faculty of Pharmacy, University of Sydney, NSW 2006, Australia Abstract: Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases.
    [Show full text]
  • REVIEW Thyroid Hormone Receptors Regulate Adipogenesis and Carcinogenesis Via Crosstalk Signaling with Peroxisome Proliferator-A
    143 REVIEW Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors Changxue Lu and Sheue-Yann Cheng Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892-4264, USA (Correspondence should be addressed to S-Y Cheng; Email: [email protected]) Abstract Peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily. They are ligand-dependent transcription factors that interact with their cognate hormone response elements in the promoters to regulate respective target gene expression to modulate cellular functions. While the transcription activity of each is regulated by their respective ligands, recent studies indicate that via multiple mechanisms PPARs and TRs crosstalk to affect diverse biological functions. Here, we review recent advances in the understanding of the molecular mechanisms and biological impact of crosstalk between these two important nuclear receptors, focusing on their roles in adipogenesis and carcinogenesis. Journal of Molecular Endocrinology (2010) 44, 143–154 Introduction (NR1C3; Fig. 1), are encoded by three different genes (PPARA, PPARD, and PPARG) located at chromosomes Peroxisome proliferator-activated receptors (PPARs) 22, 6, and 3 respectively. Upon ligand binding, PPARs and thyroid hormone receptors (TRs) are ligand- are recruited to peroxisome proliferator response dependent transcription receptors of the subfamily 1 elements (PPREs) in the regulatory region of target (NR1) in the nuclear receptor superfamily. The NR1 genes as heterodimers with the auxiliary factor RXR. group also includes retinoic acid receptors (RARs), With the PPAR/RXR heterodimers, either partner can Rev-erb, RAR-related orphan receptors (RORs), bind cognate ligands and elicit ligand-dependent oxysterol receptors (LXRs), vitamin D3 receptors transactivation (Kliewer et al.
    [Show full text]